Anja K Büscher1,2, Metin Cetiner3, Rainer Büscher3, Anne-Margret Wingen3, Berthold P Hauffa3, Peter F Hoyer3. 1. Department of Paediatrics II, Paediatric Nephrology, Endocrinology, Gastroenterology and Transplant Medicine, Children's Hospital, University of Duisburg-Essen, Essen, Germany. anja.buescher@uk-essen.de. 2. Paediatrics II, Children's Hospital, University of Duisburg-Essen, Hufelandstraße 55, 45122, Essen, Germany. anja.buescher@uk-essen.de. 3. Department of Paediatrics II, Paediatric Nephrology, Endocrinology, Gastroenterology and Transplant Medicine, Children's Hospital, University of Duisburg-Essen, Essen, Germany.
Abstract
BACKGROUND: Bardet-Biedl syndrome (BBS) is a genetic disorder with obesity as one of the major phenotypic criterion, which is proposed to be of neuroendocrine origin. Therefore, disturbances in appetite-regulating hormones have been considered as causative factors. Acyl ghrelin is an orexigenic hormone, whereas its desacylated form, obestatin, and leptin have the opposite functions. Ghrelin is negatively regulated in relation to nutritional status. The aim of this study was to evaluate the impact of hormone alterations on obesity development in BBS patients. METHODS: Total and acylated ghrelin, obestatin, leptin and adiponectin were measured in eight children with BBS. The results were analyzed in relation to auxological parameters [body mass index (BMI), height]. RESULTS: The mean BMI was significantly increased in BBS patients compared to the controls. Plasma levels of acylated ghrelin, total ghrelin and obestatin were slightly elevated in BBS patients compared to controls, as was the acyl/total ghrelin ratio. Leptin levels were significantly elevated in BBS patients. CONCLUSION: BBS patients lack the negative regulatory mechanisms of appetite-regulating hormones with respect to nutritional status and exhibit resistance to anorexigenic leptin. This results in a shift towards the orexigenic effects of this self-regulating system. These alterations may in part be responsible for the disturbed appetite regulation in BBS patients.
BACKGROUND:Bardet-Biedl syndrome (BBS) is a genetic disorder with obesity as one of the major phenotypic criterion, which is proposed to be of neuroendocrine origin. Therefore, disturbances in appetite-regulating hormones have been considered as causative factors. Acyl ghrelin is an orexigenic hormone, whereas its desacylated form, obestatin, and leptin have the opposite functions. Ghrelin is negatively regulated in relation to nutritional status. The aim of this study was to evaluate the impact of hormone alterations on obesity development in BBSpatients. METHODS: Total and acylated ghrelin, obestatin, leptin and adiponectin were measured in eight children with BBS. The results were analyzed in relation to auxological parameters [body mass index (BMI), height]. RESULTS: The mean BMI was significantly increased in BBSpatients compared to the controls. Plasma levels of acylated ghrelin, total ghrelin and obestatin were slightly elevated in BBSpatients compared to controls, as was the acyl/total ghrelin ratio. Leptin levels were significantly elevated in BBSpatients. CONCLUSION:BBSpatients lack the negative regulatory mechanisms of appetite-regulating hormones with respect to nutritional status and exhibit resistance to anorexigenic leptin. This results in a shift towards the orexigenic effects of this self-regulating system. These alterations may in part be responsible for the disturbed appetite regulation in BBSpatients.
Authors: Yanli Fan; Muneer A Esmail; Stephen J Ansley; Oliver E Blacque; Keith Boroevich; Alison J Ross; Susan J Moore; Jose L Badano; Helen May-Simera; Deanna S Compton; Jane S Green; Richard Alan Lewis; Mieke M van Haelst; Patrick S Parfrey; David L Baillie; Philip L Beales; Nicholas Katsanis; William S Davidson; Michel R Leroux Journal: Nat Genet Date: 2004-08-15 Impact factor: 38.330
Authors: K Takaya; H Ariyasu; N Kanamoto; H Iwakura; A Yoshimoto; M Harada; K Mori; Y Komatsu; T Usui; A Shimatsu; Y Ogawa; K Hosoda; T Akamizu; M Kojima; K Kangawa; K Nakao Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Jun Chul Kim; Young Y Ou; Jose L Badano; Muneer A Esmail; Carmen C Leitch; Elsa Fiedrich; Philip L Beales; John M Archibald; Nicholas Katsanis; Jerome B Rattner; Michel R Leroux Journal: J Cell Sci Date: 2005-03-01 Impact factor: 5.285
Authors: Jeannette M Beasley; Brett A Ange; Cheryl A M Anderson; Edgar R Miller Iii; Janet T Holbrook; Lawrence J Appel Journal: Obesity (Silver Spring) Date: 2008-12-04 Impact factor: 5.002
Authors: T D Müller; R Nogueiras; M L Andermann; Z B Andrews; S D Anker; J Argente; R L Batterham; S C Benoit; C Y Bowers; F Broglio; F F Casanueva; D D'Alessio; I Depoortere; A Geliebter; E Ghigo; P A Cole; M Cowley; D E Cummings; A Dagher; S Diano; S L Dickson; C Diéguez; R Granata; H J Grill; K Grove; K M Habegger; K Heppner; M L Heiman; L Holsen; B Holst; A Inui; J O Jansson; H Kirchner; M Korbonits; B Laferrère; C W LeRoux; M Lopez; S Morin; M Nakazato; R Nass; D Perez-Tilve; P T Pfluger; T W Schwartz; R J Seeley; M Sleeman; Y Sun; L Sussel; J Tong; M O Thorner; A J van der Lely; L H T van der Ploeg; J M Zigman; M Kojima; K Kangawa; R G Smith; T Horvath; M H Tschöp Journal: Mol Metab Date: 2015-03-21 Impact factor: 7.422